compounded glp-1 injections / GIP $149/mo List of approved and pending

10.1021/acschemneuro.0c00722 3 ArafaN

doi: 10.1093/carcin/14.2.183

The global market for GLP-1 weight-loss medications alone was valued at around $13.84 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 18.54%, reaching nearly $48.84 billion by 2030

Compounding pharmacies cannot legally compound it for human use without an approved new drug application

It should be noted that the abnormalities of synaptic transmission in ASD are tightly associated with mitochondrial aberrations

Pharmacovigilance of the analgesic flupirtine exemplifies the need for refined spontaneous ADR reporting